| 3.3 0.2 (6.45%) | 11-28 13:08 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.91  |
1-year : | 5.72 |
| Resists | First : | 4.2 |
Second : | 4.9 |
| Pivot price | 3.47 |
|||
| Supports | First : | 3.08 |
Second : | 2.57 |
| MAs | MA(5) : | 3.15 |
MA(20) : | 3.67 |
| MA(100) : | 2.78 |
MA(250) : | 4.35 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 2.8 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 15.53 | Low : | 1.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KA ] has closed above bottom band by 38.0%. Bollinger Bands are 50.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.26 - 3.27 | 3.27 - 3.29 |
| Low: | 3.05 - 3.07 | 3.07 - 3.09 |
| Close: | 3.06 - 3.1 | 3.1 - 3.13 |
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Tue, 28 Nov 2023
2023-11-28 | NDAQ:KA | Press Release | Kineta Inc - Stockhouse Publishing
Thu, 09 Nov 2023
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit - Yahoo Finance
Fri, 03 Nov 2023
Kineta Presents New Preclinical Data on Lead Anti-CD27 ... - GlobeNewswire
Fri, 03 Nov 2023
Kineta: Q3 Earnings Snapshot - Chron
Fri, 03 Nov 2023
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Wed, 01 Nov 2023
BCI flourishes despite widespread stock declines - BioWorld Online
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 33.2 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 101 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -10.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | 0 % |
| Operating Margin | -330.7 % |
| Return on Assets (ttm) | -141.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.57 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 12.22 |
| Price to Sales | 5.78 |
| Price to Cash Flow | -1.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2000-01-10 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|